Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 21, 2020
Daily News
May 21, 2020
- Add MSD’s 9-Valent HPV Vaccine to National Immunization Program If Approved: Lawmakers
May 21, 2020
- Nippon Shinyaku’s DMD Drug Now Available in Japan; AZ’s Lokelma, Ono’s Velexbru Too
May 21, 2020
- Pneumococcal Vaccination Rate in Children Falls Sharply amid COVID-19 Pandemic: Survey
May 21, 2020
- Zolgensma Hits Japan Market with Stringent Conditions Attached
May 21, 2020
- JCHO Hospitals to Switch from Joint to Separate Bidding for Drug Purchases after Bid-Rigging Scandal
May 21, 2020
- Don’t Give Hasty COVID-19 Nod for Existing Drugs, Follow Int’l Rules for Avigan Approval: JMA
May 21, 2020
- Nipro to Roll Out Symbicort Copy in June with Stable Supply System in Place
May 21, 2020
- Avigan Interim Analysis Not Intended to Determine Efficacy, Research Sponsor Says on Reports
May 21, 2020
- Suzuken to Exclusively Distribute Novartis’ Zolgensma in Japan
May 21, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…